- Hepion Pharmaceuticals is a biopharmaceutical company focused on drug therapy treatment for chronic liver diseases in the US.
- It's currently developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.
- Today we talk to CEO Dr. Robert Foster about the trials, differences between NASH and NAFLD and the decision to focus on cyclophilins.
For further details see:
Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)